Stem cell therapy for COPD & Lung Disease — for patients from United States

If you are researching COPD & Lung Disease treatment from the United States, the obstacle is usually access or cost: standard options have plateaued, and regenerative therapy at home runs to €18,400–€46,000. Stem Plus offers the same European GMP standard for a fraction of that — and an easy, mostly visa-free trip.

How COPD & Lung Disease is treated

Chronic obstructive pulmonary disease (COPD) involves irreversible loss of lung parenchyma (emphysema) and small-airway inflammation, progressively restricting airflow and oxygen exchange. Conventional therapy (bronchodilators, corticosteroids) suppresses inflammation but does not repair alveolar damage. Stem cell strategies target structural restoration: placental mesenchymal stem cells (MSCs) secrete hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) that stimulate alveolar regeneration and angiogenesis, partially reconstituting gas-exchange surface. Exosomes from MSCs reduce alveolar inflammation and oxidative stress. The therapeutic hypothesis challenges the dogma of irreversibility; evidence suggests modest alveolar regeneration is possible, particularly in early-to-moderate disease. Thirty-four registered trials investigate COPD cell therapy; ten actively recruit, indicating expanding clinical interest. It is delivered under a physician-led protocol and designed to complement your existing care.

Your cost from United States

Cost ranges are indicative market figures for planning, not quotes.